Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Falls in the elderly are a very common and serious health problem with devastating
consequences. Those with dementia are 5 times more likely to experience falls than older
people without significant cognitive impairment. Despite a growing awareness and the use of
available treatments, the number of falls and fall related injuries continue to increase. It
is important to develop more effective treatments to help reduce the number of falls and
prevent injury. The assessments used in this study determine fall risk which predicts the
likelihood of falls in the future.
This study will evaluate the possible role of Methylphenidate, Ritalin, in preventing falls
and improving symptoms of apathy, or indifference. Methylphenidate is FDA approved for the
treatment of ADHD but is not currently approved by the FDA for preventing falls or improving
apathy(lack of interest) in the elderly. The methylphenidate used in this study will be
absorbed through the skin by wearing a small patch near the hip area.
The specific primary aim of this open label study is to determine if use of transdermal
Methylphenidate (t-MPH) causes a reduction in fall risk in patients with dementia.
The hypotheses to be tested is that after receiving t-MPH for 4 weeks, subjects will show
improvement in gait and mobility assessment scores when compared to gait and mobility scores
at screening.